Matthew E. Peters

Matthew E. Peters

Auto-generated profile, based on publicly available information

Matthew E. Peters

Johns Hopkins University School of Medicine

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2013 in Current Psychiatry Reports
Verified
Journal Article
Closed access
PDF file
LPLaurel D. Pellegrino
Laurel D. Pellegrino
MPMatthew E. Peters
Matthew E. Peters
CLConstantine G. Lyketsos
Constantine G. Lyketsos
CMChristopher M. Marano
Christopher M. Marano

1 October 2018 in Concussion
Verified
Journal Article
Open access
MPMatthew E Peters
Matthew E Peters
RGRaquel C Gardner
Raquel C Gardner

25 April 2023 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
MPMatthew E. Peters
Matthew E. Peters
CLConstantine Lyketsos
Constantine Lyketsos

14 September 2021 in Journal of Neurotrauma
Verified
Journal Article
Closed access
HFHayley Falk
Hayley Falk
KBKathleen T. Bechtold
Kathleen T. Bechtold
MPMatthew E. Peters
Matthew E. Peters
DRDurga Roy
Durga Roy
VRVani Rao
Vani Rao
FKFrederick Kofi Korley
Frederick Kofi Korley
The lack of well-performing prognostic models for early prognostication of outcomes remains a major barrier to improving the clinical care of patients with mild traumatic brain injury (mTBI). We aimed to derive a prognostic model for predicting incomplete recovery at 1-month in emergency department (ED) patients with mTBI and a presenting Glasgow Coma Scale (GCS) score of 15 who were enrolled in the HeadSMART (Head Injury Serum Markers for Assessing Response to Trauma) study. The derivation cohort included 355 participants with complete baseline (day-of-injury) and follow-up data. The primary outcome measure was the Glasgow Outcome Scale Extended (GOSE) at 1-month and incomplete recovery was defined as a GOSE <8. At 1-month post-injury, incomplete recovery was present in 58% ( n = 205) of participants. The final multi-variable logistic regression model included six variables: age in years (odds ratio [OR] = 0.98; 95% confidence interval [CI]: 0.97-1.00), positive head CT (OR = 4.42; 95% CI: 2.21-9.33), history of depression (OR = 2.59; 95% CI: 1.47-4.69), and self-report of moderate or severe headache (OR = 2.49; 95% CI: 1.49-4.18), difficulty concentrating (OR = 3.17; 95% CI: 1.53-7.04), and photophobia (OR = 4.17; 95% CI: 2.08-8.92) on the day-of-injury. The model was validated internally using bootstrap resampling (1000 resamples), which revealed a mean over-optimism value of 0.01 and an optimism-corrected area under the curve (AUC) of 0.79 (95% CI: 0.75-0.85). A prognostic model for predicting incomplete recovery among ED patients with mTBI and a presenting GCS of 15 using easily obtainable clinical and demographic variables has acceptable discriminative accuracy. External validation of this model is warranted.

24 April 2020 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
CLChristian LoBue
Christian LoBue
JSJeff Schaffert
Jeff Schaffert
CCC Munro Cullum
C Munro Cullum
MPMatthew E Peters
Matthew E Peters
NDNyaz Didehbani
Nyaz Didehbani
CWCharles L White
Charles L White
Objective To determine whether subjects with chronic traumatic encephalopathy (CTE) and dementia have distinct clinical features compared to subjects with pathologically confirmed Alzheimer’s disease (AD). Methods Among 339 subjects assessed for CTE in the National Alzheimer’s Coordinating Center dataset, 6 subjects with CTE and 25 subjects with AD neuropathologic change matched for age (±5 years) and sex were identified. All subjects had a clinical diagnosis of dementia. Neurological examination, neuropsychological testing and emotional/behavioural data were compared between CTE and AD subjects at the time of dementia diagnosis and last clinical visit near death. Results A history of traumatic brain injury with loss of consciousness (LOC) was reported in one CTE and one AD subject; information about injuries without LOC or multiple injuries was unavailable. CTE and AD subjects did not differ significantly at the time of diagnosis or last visit on the Unified Parkinson’s Disease Rating Scale—Motor Exam, global measures of cognitive functioning (Mini-Mental State Exam and Clinical Dementia Rating Scale), emotional/behaviour symptoms as assessed with the Neuropsychiatric Inventory questionnaire or across neuropsychological measures. All CTE participants had co-occurring neuropathologic processes, including AD and most had TAR DNA-binding protein 43 (TDP-43) neuropathology. Conclusions CTE pathology was rare in a large multicentre national dataset, and when present, was accompanied by AD and TDP-43 pathologies. CTE was not associated with a different clinical presentation from AD or with greater cognitive impairment or neurobehavioral symptoms. These findings suggest that CTE may not have a distinct clinical profile when other neuropathologic processes are coexistent with CTE pathology.

23 May 2022 in Journal of the Academy of Consultation-Liaison Psychiatry
Verified
Journal Article
Closed access
BBBarry R. Bryant
Barry R. Bryant
LRLisa N. Richey
Lisa N. Richey
SJSahar Jahed
Sahar Jahed
AHAmanda Heinzerling
Amanda Heinzerling
DSDaniel A. Stevens
Daniel A. Stevens
NTNicholas T. Trapp
Nicholas T. Trapp